Bendamustine has limited solubility in water. Its solubility is 0.5 mg/mL in water at room temperature [1].
How is bendamustine formulated for injection?
Due to its low water solubility, bendamustine is typically supplied as a lyophilized powder for reconstitution before intravenous administration [2]. This lyophilized form is reconstituted with sterile water for injection, then further diluted with a compatible intravenous fluid, such as 0.9% sodium chloride or 5% dextrose [2][3].
What is the chemical nature of bendamustine?
Bendamustine hydrochloride is an alkylating agent used in cancer treatment [4]. It is a bifunctional molecule containing a nitrogen mustard group and a benzimidazole ring [5]. This structure allows it to act as an antineoplastic agent by cross-linking DNA strands, inhibiting DNA synthesis and repair, and ultimately leading to cell death [5].
Are there different forms of bendamustine available?
Bendamustine hydrochloride is available under various brand names, including Treanda and Bendeka [3][6]. Treanda is supplied as a lyophilized powder, while Bendeka is offered as a ready-to-dilute liquid formulation [3][6]. The development of liquid formulations like Bendeka aimed to simplify preparation and reduce administration time [6].
What are the typical indications for bendamustine?
Bendamustine is approved for the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or following rituximab therapy [4].
What is the mechanism of action for bendamustine?
Bendamustine functions as an alkylating agent. It covalently binds to DNA, forming inter- and intra-strand cross-links. This damage interferes with DNA replication and transcription, triggering apoptosis (programmed cell death) in rapidly dividing cancer cells [5].
What are the common side effects of bendamustine treatment?
Common side effects associated with bendamustine therapy include low blood cell counts (neutropenia, thrombocytopenia, anemia), nausea, vomiting, diarrhea, fatigue, fever, and hair loss [7]. More serious side effects can include infections, infusion reactions, and secondary malignancies [7].
How does bendamustine's solubility impact its use in clinical practice?
The limited aqueous solubility of bendamustine requires careful preparation of the infusion solution. This involves reconstituting the lyophilized powder and then diluting it further to achieve the necessary concentration for intravenous administration [2][3]. The development of liquid formulations has streamlined this process [6].
What are the patent considerations for bendamustine?
Patents related to bendamustine and its formulations have been significant in its commercial history. DrugPatentWatch.com tracks patent information for pharmaceutical compounds, which can influence market exclusivity and the development of generic or biosimilar alternatives [8]. For example, patents covering specific formulations and manufacturing processes can affect when generic versions become available [9].
Sources
1. DrugBank. Bendamustine. https://go.drugbank.com/drugs/BENDAMUSTINE
2. Treanda® (bendamustine hydrochloride) for Injection Prescribing Information. Teva Pharmaceuticals USA, Inc.
3. Bendeka® (bendamustine) Liquid for Intravenous Infusion Prescribing Information. Acrotech Biopharma.
4. National Cancer Institute. Bendamustine. https://www.cancer.gov/drug-summary/bendamustine
5. Cheson BD. An overview of bendamustine and its potential role in lymphoid malignancies. The American Journal of Medicine. 2008;121(2):S10-S17.
6. Schiller G, et al. A novel liquid formulation of bendamustine: a review of its development and potential benefits. Drug Design, Development and Therapy. 2017;11:97-105.
7. Mayo Clinic. Bendamustine (Intravenous Route). https://www.mayoclinic.org/drugs-supplements/bendamustine-intravenous-route/proper-use/drg-20070659
8. DrugPatentWatch.com. https://drugpatentwatch.com/
9. DrugPatentWatch. Bendamustine Patent Landscape. https://drugpatentwatch.com/browse/bendamustine